"Several angiogenesis inhibitors are in the market for treatment of cancer, but efficiency in terms of prolongation of survival is still very moderate. This can be explained by induction of resistance to therapy, since most agents neutralize tumor produced growth factors.An alternative and preferred strategy would be to directly target the tumor endothelial cells, which will not easily mutate to r ...